Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Onderzoek in meerdere centra om de klinische resultaten van PrimeTaper EV-implantaten bij restauraties van één tand te evalueren

11 september 2026 bijgewerkt door: Dentsply Sirona Implants and Consumables

Een open, prospectief, multicenter onderzoek om de klinische uitkomst van PrimeTaper EV-implantaat in extractieholtes en genezen richels te evalueren - een follow-up van 5 jaar

The purpose of this study is to evaluate the clinical outcome of implant survival of the PrimeTaper EV implant in single tooth restorations 1 year after permanent restoration.

Studie Overzicht

Toestand

Actief, niet wervend

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Werkelijk)

138

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Leuven, België, B-3000
        • Catholic University of Leuven
      • Alzey, Duitsland, DE-55232
        • Dental practice Dr Mischa Krebs
      • Busto Arsizio, Italië, IT-21052
        • Studio Toia
      • Apeldoorn, Nederland, 7315CA
        • Dr.F.L.Guljé, De Mondhoek
    • Iowa
      • Iowa City, Iowa, Verenigde Staten, 52242-1010
        • University of Iowa

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Adult aged 18-75 years.
  • Willing and able to sign and date the informed consent form.
  • In need of an implant in position 16 to 26 or 36 to 46, and each subject can only receive one implant.
  • Deemed by the investigator as likely to present with an initially stable implant situation.
  • A stable occlusion, i.e. an opposing natural dentition, a crown, an implant-supported fixed or removable prosthesis, a partial removable prosthesis or a full denture.
  • An adjacent tooth (root with natural or artificial crown) or an implant-supported crown mesially and distally. Exemption: If the planned implant is in the first molar position, an edentulous space is accepted distally

Exclusion Criteria:

  • Not willing to participate in the clinical investigation or not able to understand the content of the clinical investigation.

  • Unlikely to be able to comply with clinical investigation procedures according to investigator's judgement.

  • Unable or unwilling to return for follow-up visits for a period of 5 years.

  • Known allergy or hypersensitivity to titanium and/or stainless steel.

  • Uncontrolled pathological process in the oral cavity, e.g. untreated rampant caries and uncontrolled periodontal disease.

  • Uncontrolled para-functional habits, e.g. bruxism.

  • Current need of any Guided Bone Regeneration (GBR) procedure in the planned implant area (gap filling at immediate placement and soft tissue grafting are allowed).

  • Systemic or local disease or condition that would compromise post-operative healing and/ or osseointegration.

  • Immunosuppression, use of corticosteroids, per-os or intravenous bisphosphonate use, or any other medication such as anti-resorptive therapy or monoclonal antibodies that could compromise post-operative healing and/or osseointegration.

  • Any other condition that would make the subject unsuitable for participation, including but not limited to;

    • History of radiation therapy in the head and neck region.
    • History of chemotherapy within 5 years prior to surgery.
    • Present alcohol and/or drug abuse.
    • Ongoing psychiatric illness.
    • Current smoking/use of tobacco, including e-cigarettes.
  • Any ongoing disease that would make the subject unsuitable for participation, including but not limited to;

    • Recent myocardial infarction (< 3 months*).
    • Recent cerebrovascular accident (< 3 months*).
    • Recent cardiac-valvular prosthesis placement (< 3 months*).
    • Hemorrhagic diathesis.
    • Severe liver dysfunction.
    • Known or suspected current malignancy.
    • Uncontrolled diabetes mellitus.
    • Florid infection.
  • Pregnant or breastfeeding females. (Pregnancy tests will be performed as per local requirements).

  • Previous enrolment in the present clinical investigation.

  • Involvement in the planning and conduct of the clinical investigation (applies to both Dentsply Sirona staff and the clinical investigation site).

  • Simultaneous participation in another clinical investigation, or participation in a clinical investigation during the last 6 months that may interfere with the present clinical investigation.

    • < 3 months is a strict exclusion criterion. After 3 month it is up to the investigator to judge whether the subject is considered suitable for participation or not.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Single tooth restorations

A single, open-label group with patients in need of single tooth restorations will receive PrimeTaper EV implant system with diameters 3.6, 4.2, 4.8, 5.4 mm, and lengths 6.5, 8, 9, 11, 13, 15 and 17 mm.

Tapered dental implant developed by Dentsply Sirona

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Implant Survival, i.e. Number of Implants in Place Counted Clinically, 1 Year After Permanent Restoration.
Tijdsspanne: One year post permanent restoration (anticipated average 3 months after implant placement).

Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.

One year post permanent restoration (anticipated average 3 months after implant placement).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Implant Survival, i.e. Number of Implants in Place Counted Clinically, 2, 3, 4 and 5 Years After Permanent Restoration.
Tijdsspanne: 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).

Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.

2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Change of Implant Stability Quotient Value (ISQ) Between Implant Placement and Permanent Restoration.
Tijdsspanne: From date of implant placement (anticipated average 1 month after inclusion) to date of permanent restoration (anticipated average 3 months after implant placement).

Implant stability will be evaluated through ISQ value using Resonance Frequency Analysis (RFA). The stability is presented as an ISQ value. The higher the ISQ value the higher the stability. Recorded as a numeric value (1-100).

From date of implant placement (anticipated average 1 month after inclusion) to date of permanent restoration (anticipated average 3 months after implant placement).
Maximum Insertion Torque Value for Each Implant at Implant Placement.
Tijdsspanne: At date of implant placement (anticipated average 1 month after inclusion).

Maximum insertion torque value (ITV), based on ITV curve, measured in Ncm.

At date of implant placement (anticipated average 1 month after inclusion).
Final Insertion Torque Value for Each Implant at Implant Placement.
Tijdsspanne: At date of implant placement (anticipated average 1 month after inclusion).

Final insertion torque value (ITV), based on ITV curve, measured in Ncm.

At date of implant placement (anticipated average 1 month after inclusion).
Investigator Questionnaire for Each Investigational Medical Device After Implant Placement.
Tijdsspanne: Immediately after implant placement (anticipated average 1 month after inclusion).

Numerical scale 1-10, where 1 = totally disagree with the statement, and 10 = totally agree with the statement. Statements to be evaluated by the surgeon: "The implant was guided into the prepared osteotomy", "The implant followed the prepared osteotomy", "The implant has a good primary stability", "The drilling protocol is easy to use", "The implant has efficient cutting properties". Each statement will be evaluated separately.

Immediately after implant placement (anticipated average 1 month after inclusion).
Implant Success, i.e., Number of Implants Documented as Successful at 1, 2, 3 and 5 Years After Permanent Restoration.
Tijdsspanne: 1, 2, 3 and 5 years post permanent restoration (anticipated average 3 months after implant placement).

Successful implants counted, i.e. 'Yes' or 'No'. An implant will be considered successful if all of the following criteria are fulfilled:

  1. Implant in place.
  2. Lack of evidence of peri-implant radiolucency in X-ray.
  3. Less than 1mm vertical bone loss during first year after loading with permanent restoration and 0,2mm annually thereafter.
  4. Absence of persistent and/or irreversible signs and symptoms such as pain, infections, neuropathies, paresthesia, or violation of the mandibular canal.
1, 2, 3 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Change of Marginal Bone Level up to 5 Years Post Permanent Restoration Compared to Permanent Restoration.
Tijdsspanne: At permanent restoration (anticipated average 3 months after implant placement) and 1, 2, 3 and 5 years post permanent restoration.

MBL changes determined from radiographs, expressed as the distance from the implant reference point to the most coronal bone-to-implant contact on the mesial and distal side of the implant. The average will be calculated and compared for each evaluation period.

At permanent restoration (anticipated average 3 months after implant placement) and 1, 2, 3 and 5 years post permanent restoration.
Change of Probing Pocket Depth (PPD) in mm Between Permanent Restoration, and 6 Months, 1, 2, 3, 4 and 5 Years After Permanent Restoration.
Tijdsspanne: At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.

Probing Pocket Depth (PPD) measured as the distance from the mucosal margin to the bottom of the probe-able pocket in mm.

At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Presence of Bleeding on Probing (BoP), at Permanent Restoration, and 6 Months, 1, 2, 3, 4 and 5 Years After Permanent Restoration.
Tijdsspanne: At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.

Bleeding on Probing (BoP) recorded as presence or absence of bleeding when probing to the bottom of the pocket.

At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Presence of Plaque at 6 Months, 1, 2, 3, 4 and 5 Years After Permanent Restoration.
Tijdsspanne: 6 months, 1, 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).

Plaque recorded as presence or absence of plaque by visual inspection on four surfaces at each implant site.

6 months, 1, 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Occurrence of Adverse Events, Adverse Device Effects, and Device Deficiencies During the Clinical Investigation.
Tijdsspanne: Up to 5 years after permanent restoration (anticipated average 3 months after implant placement).

Adverse Events, Adverse Device Effects, and Device Deficiencies spontaneously reported, and collection at each clinical investigation visit.

Up to 5 years after permanent restoration (anticipated average 3 months after implant placement).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Andy Temmerman, Prof., KU Leuven

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

3 mei 2022

Primaire voltooiing (Werkelijk)

12 maart 2025

Studie voltooiing (Geschat)

1 mei 2029

Studieregistratiedata

Eerst ingediend

16 maart 2022

Eerst ingediend dat voldeed aan de QC-criteria

6 april 2022

Eerst geplaatst (Werkelijk)

7 april 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

11 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren